The added value of <sup>18</sup>F-FDG PET/CT compared to <sup>68</sup>Ga-PSMA PET/CT in patients with castration-resistant prostate cancer

Chen, Ruohua; Zhu, Yao; Shi, Yang; Xu, Lixin; Huang, Gang; Liu, Jianjun

doi:10.2967/jnumed.121.262250

Cited by 15 publications

(10 citation statements)

References 24 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a slow proliferation and low glucose metabolism of early PCa, and the role of 18 F-FDG in the primary stage of PCa is limited [19,20]. However, 18 F-FDG may play an important role in castration-resistant PCa and some heterogeneous tumor phenotypes with low or no expression of PSMA [21,22]. Here, we compared the new PSMA tracer 18 F-PSMA-1007 and the most commonly used clinical tracer 18 F-FDG in PET/CT scanning of the same patient.…”

Section: Discussionmentioning

confidence: 99%

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

Liu

Jiang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To explore the value of 18F-PSMA-1007 and 18F-FDG PET/CT in prostate cancer （PCa） patients, this study compared the performance of the two tracers to detect PCa and then analyzed the correlation between the metabolic parameters and serum PSA value. Finally, we evaluated the application of both tracers in the auxiliary staging of PCa patients. Methods Thirty patients diagnosed with PCa who underwent both 18F-PSMA-1007 and 18F-FDG PET/CT were enrolled. The detection rate, number, location of lesions, and metabolic parameters SUVs (SUVmax, SUVmean), PSMA-TV, MTV, TL-PSMA, TLG, and tumor-to-background ratio (TBR) were recorded and compared. The correlation between metabolic parameters and serum PSA was analyzed. Finally, the differences and consistency of both tracers for the same patient’s NM stage and clinical stage were compared. Results Patient analysis showed that 18F-PSMA-1007 PET/CT had a similar ability to identify the primary tumor and local recurrence (p=1.000) as 18F-FDG PET/CT but identified more patients with metastases (p=0.016), especially bone metastases (p=0.004). Lesion analysis showed that 18F-PSMA-1007 PET/CT identified more primary lesions, local recurrences, and metastases. It also had higher diagnostic efficacy for lymph nodes and bone metastases (both p<0.05). For lesions with positive uptake, the median SUVs and TBR of 18F-PSMA-1007 PET/CT were significantly higher than 18F-FDG PET/CT (all p<0.05). The median PSMA-TV was higher than the median MTV. Still, the difference was not statistically significant (p>0.05), while the median TL-PSMA was significantly higher than the median TLG (p<0.05). Volume-based metabolic parameters PSMA-TV, TL-PSMA, MTV, and TLG, were significantly and positively correlated with PSA (all p<0.05). In contrast, SUVs and TBR for the primary tumor or local recurrence were not associated with PSA. 18F-PSMA-1007 PET/CT identified more M1 patients and higher clinical stage, and it had higher diagnostic efficacy than 18F-FDG PET/CT (p<0.05). Conclusions 18F-PSMA-1007 PET/CT was a valuable imaging modality for PCa. It had better diagnostic efficacy, lesions detection, and a higher median value for metabolic parameters than 18F-FDG PET/CT. Volume-based metabolic parameters reflecting the total tumor burden were positively correlated with serum PSA levels. 18F-PSMA-1007 PET/CT had a higher clinical application value than 18F-FDG PET/CT for PCa patients.

show abstract

Section: Discussionmentioning

confidence: 99%

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

Liu

Jiang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…A prospective study comparing PSMA PET with FDG PET in mCRPC found 18 F‐DCFPyL PET detected more lesions than FDG PET, but there was only 22% concordance between 18 F‐DCFPyL and FDG PET 175 . A different study in CRPC patients found higher Gleason scores and PSA levels may predict development of FDG‐positive disease 176 …”

Section: Nuclear Theranostics: Lessons Learned and Future Directionsmentioning

confidence: 98%

Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting

et al. 2022

View full text Add to dashboard Cite

Introduction The 2022 Coffey−Holden Prostate Cancer Academy (CHPCA) Meeting, “Exploring New Frontiers in Prostate Cancer Research,” was held from June 23 to 26, 2022, at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA. Methods The CHPCA Meeting is an annual discussion‐oriented scientific conference organized by the Prostate Cancer Foundation, that focuses on emerging and next‐step topics deemed critical for making the next major advances in prostate cancer research and clinical care. The 2022 CHPCA Meeting included 35 talks over 10 sessions and was attended by 73 academic investigators. Results Major topic areas discussed at the meeting included: prostate cancer diversity and disparities, the impact of social determinants on research and patient outcomes, leveraging real‐world and retrospective data, development of artificial intelligence biomarkers, androgen receptor (AR) signaling biology and new strategies for targeting AR, features of homologous recombination deficient prostate cancer, and future directions in immunotherapy and nuclear theranostics. Discussion This article summarizes the scientific presentations from the 2022 CHPCA Meeting, with the goal that dissemination of this knowledge will contribute to furthering global prostate cancer research efforts.

show abstract

“…For example, Chen et al, in a study of 56 patients, found that 23.2% had at least 1 discordant lesion and that prostate serum antigen (PSA) and Gleason score were both higher in these patients (Fig. 1) (14).…”

Section: Patient Selectionmentioning

confidence: 99%

¹⁷⁷Lu-PSMA Therapy

Parent

Savir-Baruch²,

Gayed³

et al. 2022

J. Nucl. Med. Technol.

View full text Add to dashboard Cite

CE credit: For CE credit, you can access the test for this article, as well as additional JNMT CE tests, online at https://www.snmmilearningcenter.org. Complete the test online no later than September 2025. Your online test will be scored immediately. You may make 3 attempts to pass the test and must answer 75% of the questions correctly to receive Continuing Education Hour (CEH) credit. Credit amounts can be found in the SNMMI Learning Center Activity. SNMMI members will have their CEH credit added to their VOICE transcript automatically; nonmembers will be able to print out a CE certificate upon successfully completing the test. The online test is free to SNMMI members; nonmembers must pay $15.00 by credit card when logging onto the website to take the test.Radiopharmaceutical therapy using 177 Lu-prostate-specific membrane antigen (PSMA) is an effective prostate cancer treatment that was recently approved by the U.S. Food and Drug Administration. This method leverages the success of PSMAtargeted PET imaging, enabling delivery of targeted radiopharmaceutical therapy; has demonstrated a clear benefit in large prospective clinical trials; and promises to become part of the standard armamentarium of treatment for patients with prostate cancer. This review highlights the evidence supporting the use of this agent, along with important areas under investigation. Practical information on technology aspects, dose administration, nursing, and the role of the treating physician is highlighted. Overall, 177 Lu-PSMA treatment requires close collaboration among referring physicians, nuclear medicine technologists, radiopharmacists, and nurses to streamline patient care.

show abstract

The added value of ¹⁸F-FDG PET/CT compared to ⁶⁸Ga-PSMA PET/CT in patients with castration-resistant prostate cancer

Cited by 15 publications

References 24 publications

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting

¹⁷⁷Lu-PSMA Therapy

Contact Info

Product

Resources

About

The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer

Cited by 15 publications

References 24 publications

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting

177Lu-PSMA Therapy

Contact Info

Product

Resources

About

The added value of ¹⁸F-FDG PET/CT compared to ⁶⁸Ga-PSMA PET/CT in patients with castration-resistant prostate cancer

¹⁷⁷Lu-PSMA Therapy